In Part 4 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On what late-stage setbacks and tolerability trade-offs reveal about portfolio planning and platform expansion.

In Part 3 of our Series on how the pharma landscape is being reshaped - from the inside out - we have Eyes On where late-stage clinical execution is still cutting through uncertainty as de-risked assets redefine standards of care and company trajectories.

In Part 2 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how policy and regulation are redefining pricing, access, and market stability.

In Part 1 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how cost discipline, manufacturing shifts, and portfolio resets are reshaping large pharma.

MFN — once a policy abstraction — is now reshaping corporate strategy, pricing frameworks, and commercialization models.